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Abstract
New methods for the evaluation of accuracy and precision are mentioned in the latest edition of the United States
Pharmacopoeia (USP), whereas other validation parameters, that is, selectivity, linearity, range, and robustness, remained
relatively unchanged. In obtaining reliable data from any chemical/pharmaceutical analysis, the analytical procedure must
be validated or verified in accordance with the latest edition of the pharmacopoeia. Some review articles on the general
validation methods have been published by the author. This present review will focus on the implementation and discussion
of the accuracy and precision evaluation based on the current USP and Indonesian pharmacopoeia. Some examples of the
calculation of several accuracy and precision method of determinations are also discussed.
Keywords: accuracy, intermediate precision, repeatability, validation method

establishing analytical performance characteristics of
accuracy, precision, and detection limit. Accuracy can
only be evaluated if a true or accepted reference value is
available. Accuracy of an analytical procedure expresses
the closeness of agreement between τ (true or nominal
value) and Y (measured value); the closeness is
expressed as the average of (Y − τ). General chapter
USP44-NF39 <1010> [7] provides a basic statistical
approach for decision-making and the methods for
comparison of two analytical procedures; comparing two
analytical procedures (e.g., new- and validated-method)
is necessary to determine whether the difference of the
accuracy and precision are less than the amount described
in the analytical target profile (ATP). General Notices
and Requirements Section 6.30 of the USP [8] describes
the need to produce comparable results from the
proposed/alternative to the compendial method. This
comparative test described in general chapter USP 44-NF
39 <1010> can be also applied to the method validation
for transferring analytical procedures in different
laboratories [7]. The performance characteristic of
accuracy and precision, which should be evaluated and
specified in the method validation, must meet the
acceptance criteria described by the ATP of the
proposed/new method [9]. Review articles on the
validation of analytical methods and their applications in
pharmaceutical analysis (including herbal drugs) have
been published by the author in 2005 [10], 2012 [11],
2018 [12, 13], and 2022 [14, 15]. In the last 4 years, new
methods for the evaluation of accuracy and precision are
mentioned in the latest edition of the US, whereas other

Introduction
Based on the general chapter of United States
Pharmacopoeia (USP)–National Formulary (US44NF39) <1225> [1], the accuracy of the analytical
procedure can be defined as the closeness of test results
obtained by that procedure to the true value. The
accuracy of an analytical procedure should be established
across its range, whereas precision is the degree of
agreement among individual test results when the
procedure is applied repeatedly to multiple samplings of
a homogeneous sample. The definition of accuracy and
precision in the general chapter USP-NF39 <1225> is
almost similar to their definition in British Pharmacopeia
(BP) 2022, Supplementary III F [2], International
Council for Harmonization (ICH) Q2R1 [3], and
Indonesian Pharmacopoeia (FI) VI <1381> [4]. The ICH
of Technical Requirements for Pharmaceuticals for
Human Use Q2R1 uses the term trueness instead of
accuracy. According to International Organization for
Standardization (ISO) 5725-2:2019 [5], the term
accuracy indicates the combination of the term trueness
and precision. General chapter USP44-NF39 <1225> and
FI VI <1381> [1, 4] describe general validation methods
of analytical procedures and their acceptance criteria; the
method performance is determined using the parameters
accuracy, precision, specificity, detection limit,
quantification limit, linearity, and range. General chapter
USP44-NF39 <1210> [6] describes the utilization of
statistical approaches in procedure validation as
described in chapter <1225> [1]. This chapter focuses on
227

December 2022  Vol. 26  No. 4

228 Indrayanto, et al.

validation parameters, that is, selectivity, linearity, range,
and robustness, remained relatively unchanged. The
analytical method must be validated/verified based on the
latest edition of the pharmacopoeia or official guidelines
to obtain reliable data from any chemical analysis carried
out by QC or research laboratories; if a new edition of the
pharmacopoeia has been released, then the old version
will automatically no longer be applied.
This review will describe and focus on implementing
accuracy and precision evaluation in accordance with the
current USP44-NF39 [1, 6, 7, 9] and FI VI [4]. It also
aims to gain a comprehensive understanding of the new
methods for determining accuracy and precision based on
those current Pharmacopoeias. Related official guidelines,
publications, and some similarities from previous
editions of the USP-NF will be described in this review
because of their important role in current evaluation
methods. Some examples of calculations and
determinations of accuracy and precision are also
described. Given their comprehensive understanding of
accuracy and precision evaluation methods, the
pharmacists in QC laboratories and/or researchers can
select the best method for a particular application in their
work.

Assessment of Accuracy and Precision
Separated Evaluation of Accuracy and Precision:
According to chapters USP44-NF39 <1225> [1] and
FI VI <`1381> [4]. Accuracy can be determined by three
categories: (1) Drug substance: accuracy is determined
by applying an analytical procedure to an analyte of
known purity (e.g., a certified reference standard) or by
comparing with a well-characterized procedure, where
the accuracy has been stated or defined. (2) Drug in
product: accuracy can be determined by applying an
analytical procedure to a synthetic mixture of the drug
product components to which a certain amount of analyte
is added within the range of the procedure. If a sample
with all components of the drug product can be obtained,
that is, active pharmaceutical ingredient (API) and
excipients, then this can be done by adding a known
amount of analyte to the drug product (spiking) or by
comparing with a well-characterized procedure, where
the accuracy has been stated or defined. (3) Impurities:
accuracy should be assessed on a sample (of drug
substance or drug product) that is spiked with a known
amount of impurity.
Accuracy should be assessed using a minimum of nine
determinations over a minimum of three concentration
levels, covering the specified range (i.e., three
concentrations and replicates of each concentration). The
accuracy can be evaluated as follows: (1) Determine the
percent of recovery (%R) across the range of the assay.
(3) Evaluate the linearity of the relationship between the
estimated and actual concentrations. The statistically
Makara J. Sci.

preferred criterion indicates that the confidence interval
(CI) for the slope is contained within an interval of about
1.0 or alternatively, that is, the slope is close to 1.0.
%R can be calculated using Equation 1 or 2 (standard
addition method).
𝑌𝑓

%R =

𝑌𝑐

× 100

(1)

or
%R =

𝑌𝑓 −𝑌𝑢
𝐶𝑎

× 100

(2)

where Yc is the actual or true concentration, Yf is the
measured/estimated concentration, Yu is the original
concentration before standard addition, and Ca is the
added concentration of the analyte. The acceptance
criteria of certain drug substance or product are described
by their USP-NF and FI monographs, or it can be referred
to Tables 1 and 2 (if the monograph is not yet available).
The acceptance criteria depend on analyte concentrations
in samples or the instrument used, which should be stated
in the ATP of the proposed method. Researchers must
decide whether the acceptance criteria to be specified in
the ATP are based on the concentration of API in the
sample and/or the instrument used. Food and Drug
Administration Office of Regulatory Affairs Laboratory
Manual II [16] describes that the general acceptance
criteria of accuracy for human drug analytical methods is
at least 80%–120% (for assay) and 70%–130% (for
content uniformity) of the expected content.
USP <1225> [1] and FI <1381> [4] do not describe the
method for the evaluation of the linearity relationship of
the recovery curve between Yf and Yc (Equation 3). Funk
et al. [28] described the equations used to determine the
CI of the slope (b) and intercept (a) (Equations 4 and 5)
of the recovery curve. The CI value must include the
value of 1 (slope) and 0 (intercept); if it does not include
the respected values, then one may assume a constant
and/or proportional systematic error of the proposed
method.
Yf = a + b.Yc
CIb = b ±
Sy = √

∑[𝑌𝑖𝑓 −(𝑎+𝑏. 𝑌𝑖𝑐 )2
𝑛−2

(3)

𝑡 .𝑆𝑦

(4)

√𝑄𝑋𝑋
1

; QXX = ∑ 𝑌𝑖𝑐2 − (∑ 𝑌𝑖𝑐 )2
𝑛

1

𝑌̅𝑐2

𝑛

𝑄𝑋𝑋

CIa = 𝑎 ± 𝑡. 𝑆𝑦 √( +

)

(5)

i (1, 2 …. n) indicates different concentration levels, and
t is the student-t-factor based on the degree of freedom of
n − 2 (p = 0.05). Recently, ICH Q14 described that the
slope of the recovery curve between Yf and Yc should be
within 0.8 to 1.25 (for p = 0.05) [29].
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Table 1. Acceptance Criteria of Accuracy and Precision*

Concentration (C)

%Recovery Limit

100%
10%
1%
0.1%
0.01%
10 µg/g (ppm)
1 ppm
10 µg/kg (ppb)

98–101
95–102
92–105
90–108
85–110
80–115
75–120
70–125

% Bias Limit
(λ)**
−2 to +1
−5 to +2
−8 to +5
−10 to +8
15 to +10
−20 to 15
−25 to +20
−30 to +25

Sr***

SR***

1
1.5
2
3
4
6
8
15

2
3
4
6
8
11
16
32

*Data from Ref. [17]; ** calculated from % Recovery; ***Limit of Sr (repeatability) and SR (intermediate precision) are
calculated as RSD/CV. The acceptance criteria of the cumulative variance in laboratories (SR) can be estimated as 1.6 × Sr;
Sr and SR can also be estimated using equation 2C−0.15 (C is the mass fraction) [17].
Table 2. Acceptance Criteria of the Accuracy and Precision of Various Instruments

Accuracy (%)
Instrument
MIR
NIR
UV/VIS
AAS
ICP
Fluorescence
Spectroscopy
Raman
NMR
MS
Chromatography*

Precision (% RSD)
Ref.
Repeatability
Intermediate precision
DS DP
I
DS
DP
Imp.
1
2
20
1
3
25
18
1
2
20
1
3
25
19
1
2
15–20
1.5
3
15–25
20
5
5
20
8
8
25
21
5
5
20
8
8
25
22

DS

DP

Imp.

98–102
98–102
98–102
95–105
Na

95–105
95–05
95–105
95–105
95–105

70–150
70–150
80–120
70–150
70–150

98–102

95–105

80–120

1

2

20

1

3

25

23

98–102
98–102
Na
Na

95–105
95–105
80–120
Na

70–150
80–120
50–120
Na

1
1
Na
Na

2
2
Na
Na

20
20
Na
Na

1
1
Na
Na

3
3
Na
Na

25
25
Na
Na

24
25
26
27

DS: drug substance, DP: drug product, Imp: impurities, Na: not available. *The acceptance criteria can be referred to the detector
of the chromatographic system.

In general, the precision of an analytical procedure is
expressed as the standard deviation (SD), relative
standard deviation (RSD), or coefficient of variation
(CV) of a series of measurements [1, 4]. Three levels of
precision determination include repeatability, intermediate
precision (ruggedness), and reproducibility [30].
Repeatability refers to the use of an analytical procedure
within a laboratory over a short period of time using the
same analyst with the same equipment. Intermediate
precision (also known as ruggedness) expresses withinlaboratory variation, as on different days, or with
different analysts or equipment within the same
laboratory. Reproducibility refers to the use of an
analytical procedure in different laboratories, as in a
collaborative study [1, 4].
Precision is determined by testing a sufficiently
homogenous sample aliquot and expressed as SD or
Makara J. Sci.

RSD. Sample analysis must be performed through a
complete analytical procedure from sample preparation
to final test result. Repeatability must be assessed using
a minimum of nine determinations covering the specified
range of the procedure (i.e., three concentration levels
and three replicates of each concentration) or using a
minimum of six determinations at 100% of the test
concentration [1, 4]. For analysis using a single run, SD
can be calculated using Equation 6.
̅ 2
∑𝑛
𝑖=1(𝑌𝑖 −𝑌)

SD = √

𝑛−1

; RSD = CV =

𝑆𝐷
𝑀𝑒𝑎𝑛

× 100%

(6)

where Yi is the individual value, and 𝑌̅ is the sample
mean. Current Pharmacopoeias [1, 4] do not include
equation for calculating the intermediate precision (SR);
SR can be calculated using Equation 7 as described by
Ermer [30] and discussed in a previous review
December 2022  Vol. 26  No. 4
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article [11]. Based on Ref. [30], SR can also indicate
reproducibility.
SR = √𝑆𝑟2 + 𝑆𝐵2

(7)

where Sr is the repeatability, and SB is between condition
variance; SB, Sr, and SD of the mean (SDm) can be
determined using ANOVA (Equations 8 and 9), which
were described in the previous edition of the USP41NF36, 2018 [31]. Detailed discussions can be referred to
author’s previous publication [11], but the equations
were not mentioned in the current edition of the USP [7].
SB =

𝑀𝑆𝑏𝑒𝑡𝑤𝑤𝑒𝑛 − 𝑀𝑆𝑤𝑖𝑡ℎ𝑛

(8)

𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑒𝑠 𝑝𝑒𝑟 𝑟𝑢𝑛

Sr = √𝑀𝑆𝑤𝑖𝑡ℎ𝑛

(9)

The previous edition of the USP [31] described the
variance of the mean (Vm) for a test involving different
combinations of runs and number of replicates per run
using (Equation 10):
Vm =

𝑆𝐵
𝑚

+

𝑆𝑟

(10)

𝑚.𝑛

SDm = √𝑉𝑚
where m is the number of runs, and n is the number of
replications for each of run. Equation 10 is no longer
described in the current edition of the USP-NF [7]. For
in-house validation of a new analytical procedure, the
author recommends determining SR instead of Sr for
precision evaluation. The precision acceptance criteria of
certain drugs and preparations have been described by the
monographs of the pharmacopoeia or Tables 1 and 2.
FDA, ORA Laboratory Manual II [16] describes the
general acceptance criteria for the precision of human
drug analytical methods, which are <3% (for drug
products) and <2% (for API).
General chapter of USP44-NF39 <1210> [6]. Accuracy
and precision can be evaluated using CI of bias (CIB) and
CI of SD (CISD).
CIB = (𝑌̅ − τ) ± 𝑡1−𝛼,𝑛−1 ×
CISD = SD √

𝑛−1

2
𝛸𝛼:𝑛−1

SD = √

𝑆𝐷
√𝑛

(11)
(12)

̅
∑𝑛
𝑖=1(𝑌𝑖 −𝑌 )
𝑛−1

where τ is the true or nominal value, bias (B) is (𝑌̅ − τ), n
is the number of reportable value, t1−α,n−1 is the percentile
of central t-distribution with area 1 − α to the left and
2
(n − 1) degrees of freedom, 𝛸𝛼:𝑛−1
is a percentile of a
Makara J. Sci.

central chi-squared distribution with area α to the left,
and (n − 1) degrees of freedom.
The acceptance criteria of CIB and CID can be referred to
Tables 1 and 2. If λ is the maximum bias acceptance limit,
then CIB must be between −ƛ and +ƛ, and CISD should be
less than the acceptance values. If the nominal content of
the API is 0.1% (Table 1), then CIB should be within
−10% to +8%, and CISD must be <3% (repeatability) or
<6% (reproducibility). If the researcher using NIR (Table
2) limit of %ƛ ranging from −2% to +2% (DS), from −5%
to +5% (DP), or from −30% to +50% (impurities). The
researcher must determine whether to use acceptance
criteria based on nominal concentration or the instrument
used must be described in ATP.
Combined evaluation of accuracy and precision.
Using separated accuracy and precision as discussed in
section separated evaluation of accuracy and precision,
some data of the individual results of Yi or %R are not
included in the required acceptance criteria (Tables 1 and
2). Several methods used for evaluating accuracy and
precision simultaneously have been proposed to ensure
that all Yi or %R can meet the requirement of the
acceptance criteria; discussion of this method has been
described by a previous review [12].
The general chapter USP44-NF39 <1210> [6] describes
the methods for the simultaneous assessment of accuracy
and precision. Yi or %R should fall between (−λ + τ) and
(λ + τ), indicating that 𝑌̅ ± prediction interval
(PI)/tolerance interval (TI) must be included in the
permitted specification range (Tables 1 and 2).
Mean ± PI = 𝑌̅ ± 𝑡(1+𝑃)/2,𝑛−1 × SD √1 +
Mean ± TI = 𝑌̅ ± K. SD

K=√

2
𝑍1+𝑃
𝑋 (𝑛−1)
2
2
𝛸𝛼,𝑛−1

1
𝑛

(13)
(14)

1

𝑥(1 + )
𝑛

where t(1+P)/2, n−1 is the percentile of a central t-distribution
with area (1 + P)/2 to the left and (n − 1) degrees of
2
freedom, 𝑍!+𝑃/2
is the square of the standard normal
2
percentile with area (1 + P)/2 to the left, and 𝛸𝛼,𝑛−1
is the
chi-squared percentile with area α to the left and (n − 1)
degrees of freedom.
Japan Pharmacopeia 17th edition [32] used 𝑌̅ ± CI to
assess accuracy; CI must be calculated using
intermediate precision or reproducibility. 𝑌̅ ± CI should
be included in the range of the acceptance criteria (Tables
1 and 2). The application of CI (p = 0.05) in evaluating
recovery was also recommended by the new version of
ICH Q2 (R2) [33].
December 2022  Vol. 26  No. 4
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In evaluating the percent of the data (𝑌̅ ± CI/PI/TI)
included in the required specification range (P%)inside can
be calculated using Excel [34]:

|µ𝐷 | must be less than the required value (d). For
precision, the SD ratio of the new procedure to the old
procedure must be less than a certain required value (k).
𝑆𝐷𝑁

P (%) inside = NORM.DIST(SLupper; µ;SD;TRUE) −
NORM.DIST(SLlower;µ;SD;TRUE)
(15)
where SLupper, lower is the upper or lower specification limit
of the ATP. These discussions show that every results of
the pharmaceuticals analysis at QC laboratory (𝑌̅ ±
CI/PI/TI) should be included in the acceptance criteria
(Tables 1 or 2), or P (%)inside should be close to 100%.
The author recommends applying this combination
methods rather than the separate methods, which are
discussed in section separated evaluation of accuracy and
precision.
Selection of SD and the methods of evaluations. As
previously discussed, SD can be calculated as Sr, SR, and
SDm. For analysis, which is performed using several
series of measurements (runs), the values of SR would be
> Sr and >SDm as shown by a previous work [35]. SD can
be applied for a single run of analysis. Calculations of
accuracy and precision using Equations 11–15 require
SD value; the results of calculation of the mean ± PI/TI
(Equations 13 and 14) yield broadest expected ranges, if
SR is used as SD; this shows that the application of SR as
SD is the best choice. Our work [35] showed that the
calculation of ̅̅̅̅̅
%𝑅 and precision using separate
evaluations (Equations 1, 2, 4, 5, 11, and 12) and the
combination evaluation (Equation 13) met the acceptance
criteria of the ATP, but calculation using Equation 14
showed that some data were out of specification (OOS).
Therefore, the combination evaluation using TI
(Equation 14) is recommended for the evaluation of
accuracy and precision because it could yield a broader
calculated expected range. If Equation 14 is used, and the
specification range of the ATP is achieved, then using
other equations will also meet the ATP. Detailed
discussion regarding this matter has been described in
previous publication by the author [12].

𝑆𝐷𝑂

Comparing the accuracy of two procedures, the absolute
value of the true difference in means (µ𝐷 ) can be
calculated as follows.
|µ𝐷 | = |µ𝑁 | − |µ𝑂 |

Makara J. Sci.

(16)

must be < k

(17)

If an old procedure has µO of 100 unit, then upper and
lower specification limits are 104 and 96, respectively,
CVO is 0.16, and CVlot variance is 0.64. The probability of
OOS for several values of d and k can be estimated as
follows:
Prob (OOS) = 1 − ∅ (

104−(100+𝑑)

√0.64+𝑘 2 𝑥0.16

) + ∅(

96−(100+𝑑)
√0.64+𝑘 2 𝑥 0.16

) (18)

where ∅ represents the cumulative probability function
of the normal standard distribution. Table 3 describes the
expected OOS of the new procedure for various d and k
values. If d = 1 and k = 2 is selected, then the OOS of the
new procedure will be 0.14%; if d = 2 and k = 1, then
OOS will be 1.27%. OOS of an analytical procedure can
be calculated using Equation 19 [36]:
Prob (OOS) = 2. ∅ (−3. Cp)

(19)

where ∅ represents the normal standard cumulative
distribution function (Z value), and the process capability
(CP) can be estimated using Equation 20 [12].
Cp =

𝑆𝐿𝑢𝑝𝑝𝑒𝑟 −𝑆𝐿𝑙𝑜𝑤𝑒𝑟

(20)

6 𝑆𝐷

OOS can also be estimated by 100% minus P (%) inside
(Section assessment of the accuracy and precision
through comparison).
Based on BP 2022 [2], the accuracy evaluation of two
procedures could be evaluated using cross-correlation
coefficient r (Pearson Product–Moment Correlation). If
N is the proposed procedure, then O is the validated
procedure. r can be calculated using Equation 21 [37]:

Assessment of the Accuracy and Precision
Through Comparison
Principle of evaluation. Based on USP44-NF39 <1225>
[1], accuracy and precision of the proposed/new (N)
method can be validated by comparing with the old (O)
validated method. The detailed comparison methods
have been described by the current USP [7], which will
be discussed below.

231

r=

𝑛(∑ 𝑌𝑁 .𝑌𝑂 )−(∑ 𝑌𝑁 ).(∑ 𝑌𝑂 )

(21)

2 )−(∑ 𝑌 )2 ][𝑛( 𝑌 2 )−(∑ 𝑌 )2 ]
√[𝑛(∑ 𝑌𝑁
𝑁
𝑂
𝑂

Based on ICH M10 [38], the assessment of the accuracy
by comparison can be evaluated using the concordance
correlation coefficient (CCC) as described by Equation
22 [39].
Table 3. OOS percentage (%) of the New Procedure*

d
0
1
2

k=1
0.001
0.04
1.27

k = 1.5
0.01
0.14
2.28

k=2
0.04
0.40
3.85

*Modified from Ref. [7]
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2𝑟. 𝑆𝐷𝑁 . 𝑆𝐷𝑂
2
2
2
𝑁 −𝑌𝑂 ) + 𝑆𝐷𝑁 +𝑆𝐷𝑂

CCC = (𝑌

(22)

CCC of 0.90, 0.90–0.95, 0.95–0.99, and >0.99 indicates
poor, moderate, substantial, and perfect, respectively
[40].

Comparison of two procedures using nonhomogenous test materials (variation across test
samples) [7]. For this paired design using nonhomogenous samples (different lots and manufactures),
the number of replications can be estimated as follows:
2

Evaluating the accuracy and precision of the proposed
procedure by comparing with a validated procedure using
a significance test with a certain level of p is not
recommended [41, 42].
Comparison using homogenous test materials [7]. The
number of replications of the new procedure (nN) and the
old procedure (nO) can be calculated using Equation 19.
(𝑍1−𝛼 + 𝑍1−𝛽)𝑥 𝑆𝐷𝑂

nN = nO = 2 × (

𝑑−|µ𝐷 |

)2 + 1

(21)

where Z1-α and Z1-β are the standard normal percentiles
with area 1−α and 1−β, respectively, to the left. The Type
I error rate is α, and the Type II error rate is β. Table 4
presents the power (1 − β) for sample size combination
with d = 1, k = 2, α = 0.05, and SD N = SDO = 0.4 (for µ
of 100 unit). Samples size should be 15 to obtain around
0.80 power of the new procedure. The accuracy of the
two procedures is tested by calculating CI of µ D, which
should be fulfilled −𝑑 < 𝜇𝐷 < +𝑑, and CISD must be
<k.
2
𝑆𝐷𝑁

𝐶𝐼𝜇𝐷 = 𝑌̅𝑁 − 𝑌̅𝑂 ± 𝑡1−𝛼:𝑑𝑓 √

𝑛𝑁

+

2
𝑆𝐷𝑂

𝑛𝑂

(22)

2 2
𝑆𝐷2
𝑁 +𝑆𝐷𝑂 )
𝑛𝑁
𝑛𝑂
𝑆𝐷4
𝑆𝐷4
𝑁
+ 2 𝑂
(𝑛
𝑛2
−1)
𝑛
𝑁
𝑁
𝑂 (𝑛𝑂 −1)

𝑛=(

2 +𝑆𝐷2
(𝑍1−𝛼 +𝑍1−𝛽)𝑥√𝑆𝐷𝑁
𝑂

𝑑−𝜇𝐷

CISD =

𝑆𝐷𝑁

̅ ± 𝑡0.95;𝑛−1 ± √
𝐶𝐼𝐷̅ = 𝐷
𝐶𝐼 𝑜𝑓 𝑆𝐷𝐷̅ = √

1

(23)

where t1−α:df is a quantile from a central t-distribution with
area 1 − α to the left and degrees of freedom (df), and Fα,
nN−1, nO−1 is the F-quantile with area α to the left and
degrees of freedom nN−1 and nO−1.
Table 4. Power Values for Noninferiority Test (α = 0.05)*

Homogenous Test
Materials
n
Power
8
0.528
14
0.781
15
0.808
19
0.890
20
0.904

Variation Across
Test Material
n
Power
8
0.391
17
0.775
18
0.803
22
0.885
23
0.901

*Data from Ref. [7]; α: Type I error, Power = 1 − β (β is Type
II error), d = 1, k = 2, and SD1 = SD2 = 0.4 for 𝑌̅2 of 100 units;
n = required replications.
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2
𝑆𝐷𝐷

𝑛

2
(𝑛−1).𝑆𝐷𝐷

(25)

(26)

2 ×𝛸 2
𝑆𝐷𝑂
𝛼:𝑛−1

2
where 𝛸𝛼:𝑛−1
is the percentile from the chi-squared
distribution with area α to the left and degrees of freedom
n − 1.

If SDO is not available, then the CI of the SD ratio can be
calculated as follows:

𝑆𝐷𝑁 =

𝑆𝐷𝑂 √𝐹∝,𝑛𝑁 −1,𝑛𝑂 −1

(24)

Table 4 presents the power (1−β) for sample size
combination with d = 1, k = 2, α = 0.05, and SDN=SDO =
0.4 (for µ of 100 unit). If the required power is 0.80, then
the number of samples for new and old procedures should
̅ ) for a
be 18. The 90% CI on the difference of means (𝐷
paired design used to test equivalence of means was
calculated as follows.

(

𝑑𝑓 =

) +1

𝑆𝐷𝑂 =
𝐶𝐼 𝑜𝑓

∑𝑛
𝑗=1.(

𝑌𝑗𝑁1 −𝑌𝑗𝑁2
√2

2

̅𝑁 )
−𝐷

𝑛−1
∑𝑛
𝑗=1.(

𝑆𝐷𝑁
𝑆𝐷𝑂

𝑌𝑗𝑁1 −𝑌𝑗𝑁2
√2

2

̅𝑂 )
−𝐷

𝑛−1

=

𝑆𝐷𝑁
𝑆𝐷𝑂

√𝐹

(27)

1

𝛼,𝑛−1,𝑛−1

(28)
(29)

Summary of the comparison method. Accuracy
evaluation by using the comparison method has been
mentioned by the USP44-NF39 chapter <1225>, BP
2022, and Indonesian pharmacopoeia chapter <1381> [1,
2, 4]. The USP 44-NF 39 chapter <1010> [7] described
detailed methods for the evaluation of accuracy and
precision using the comparison method (Sections internal
quality control). BP 2022 [2] used cross-correlation as
the method of assessment. However, Indonesian
Pharmacopeia [4] did not describe the evaluation method
of the accuracy using the comparison method. In
comparing two bioanalytical methods, ICH M10 [38]
used CCC (Section principle of evaluation). Several
applications of CCC in bioanalytical methods have been
reported; thus, the application of CCC is recommended
instead of using cross-correlations. Further work must be
December 2022  Vol. 26  No. 4
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conducted to determine whether CCC can be applied to
replace the complex method described by USP 44-NF39
<1010> [7]. The comparison of two procedures (N and
O) should not be evaluated using a significance test with
a certain p-value; p-value cannot be trusted whether it is
small or large [41, 42].

Equation 4: CIb = 0.898 ± t
1.181
√18562.5

Once the proposed method has been validated using
separate or combined evaluations as discussed in sections
assessment of accuracy and precision–internal quality
control, the validated method should always be
monitored during its application [9, 43, 44]. A certain
number of QC samples should be analyzed during routine
analysis. QC samples are typical samples which over a
given period are sufficiently stable and homogeneous
enough to provide the same results [43]. For each batch
of run, 5% QC samples should be analyzed [43, 44]. For
every 20 samples, one QC sample should be analyzed.
The results of QC sample analysis can be divided into the
acceptance zone (between lower and upper limit), guard
band, and rejection zone [9]; or limits are set as mean ±
2 SD, mean ± 3SD (action limit) [43]; or mean ± 1 SD
(zone C), mean ± 2 SD (zone B), and mean ± 3 SD (zone
A) [44]. Based on the general chapter of USP <1210> and
<1010> [6, 7], it can be assumed that the acceptance zone
is mean ± CI/PI, whereas the guard band is mean ± TI. In
proving whether the method used is still valid during
application, the result of the analysis of all QC samples
should be included in the acceptance zone or zones C and
B. If the results are in the guard band, action limit,
rejection zone, or zone A, then the analytical procedure
should be investigated to correct the problem or to be revalidated as necessary. This method can no longer be
used for routine applications. The author recommends
that the internal quality control methods should be added
in the new edition of Indonesian Pharmacopeia [4] and
Indonesian’s CPOB [45].

Example of Calculations

(tn − 2,0.05 = 2.306) = 2.306.

= 0.898 ± 2.306 × 0.00867 = 0.878 to 0.918, or

0.878 ≤ 𝑏 ≤ 0.918 (not include 1: a proportional error
is observed); Equation 5: CIa = 3.746 ± 2.306 ×
1.181√(

Internal Quality Control

𝑆𝑦
𝑄𝑥𝑥

233

1
10

+

167.52

) = 3.746 + 2.306 × 1.499 = −7.02 to

1856.5

−0.289; or −7.02 ≤ 𝑎 ≤ − 0.289, (not include 0:
constant systemic error is observed).
These data indicate that the researchers should optimize
the extraction methods. The proportional and systemic
error of the method cannot be observed using %R, RSD
of precision, and slope. The calculation of CI a, CIb, and
other validation parameters can be performed using our
self-developed VMA solutions, which can be
downloaded for free using the described link [46].
Determination of Accuracy According to Ref. [6].
Drug substances. Table 6 shows the analysis data of a
DS in three levels of API concentration in triplicate using
NIR. As shown in Table 2, the acceptance criteria of the
bias of the accuracy is −2% to +1%, and the RSD of
repeatability and intermediate precision is 1%.
Table 5. Drug product*

Sample
1
2
3
4
5
6
7
8
9
10
̅̅̅
𝑋̅𝑐
̅̅̅̅̅ (RSD)
%𝑅

Xc (ppm)
100
115
130
145
160
175
190
205
220
235
167.5

Xf (ppm)
87
100
113
125
141
152
166
181
193
209

%R
87.0
115.0
86.9
86.2
88.1
86.9
87.4
88.3
87.7
88.5
87.4 (0.96)

*Modified from Ref. [28]

Determination of %R and recovery curve based on
Ref. [1] and [4]. Table 5 shows the analysis result data
of an API in a DP (10 level of concentrations) using a UV
spectrophotometer; this work aims to investigate
systemic and constant proportional errors during
extraction. As shown in Table 1, the acceptance criteria
for accuracy is 85%–110%, and repeatability is 4%
(concentrations of 100 ppm).
1

̅̅̅̅̅ = ∑10 %𝑅 = 87.4, SD = 0.84, RSD = 0.96%; the
%𝑅
10
recovery and precision meet the requirements.
The recovery curve is Xf = 0.898 Xc − 3.745, r = 0.999;
Qxx = 18562.5; Sy = 1.181; slope meets the requirement
of ICH Q14 [29].

Table 6. Drug Substance*

Level
Concentration
1
1
1
2
2
2
3
3
3
̅̅̅̅̅
%R
RSD

Xc (ppm)

Xf (ppm)

%R

500
500
500
1000
1000
1000
1500
1500
1500

498.0
494.2
498.0
987.2
990.5
999.4
1499.5
1490.5
1481.6

99.6
98.8
99.6
98.7
99.1
99.9
99.9
99.3
98.8
99.3
0.48

*Modified from Ref. [6]

Makara J. Sci.

December 2022  Vol. 26  No. 4

234 Indrayanto, et al.

Separated evaluation of accuracy and precision.
Equation 1: % 𝑅̅ = 99.32, RSD = 0.49%, Equation 4: CIb
= 0.99380 ± 0.011600; Equation 5: CI a = −0.58889 ±
12.530 (p = 0.05).
Equation 11: CIB = (99.3% − 100%) ± 1.86 x

0.48
√9

=

−0.7 ± 0.298 = −0.99% to −0.40%; Equation 12: CISD
= 0.48 √

9−1
2.73

= 0.82. This evaluation indicates that CIB

and CISD meet the acceptance criteria shown in Table 1
(see 2. 1).
Combined evaluation of accuracy and precision.
1
Equation 13: 𝑌̅ ± 𝑃𝐼 = 99.3 ± 1.86 × 0.48√1 + = (99.3
9

± 0.94)% = (98.4 to 100.2)%
Equation 14: 𝑌̅ ± 𝑇𝐼 (𝑘 𝑥 𝑆𝐷) = 99.3± 𝑘. 0.48 = 99.3 ±
k. 0.48 = 99.3 ± 2.63 × 0.48 = 98.04% to 100.56% (meet
the acceptance criteria, see 2. 2.)

k=√

𝛧 1+𝑃
𝑥 (𝑛−1)
(
),𝑛−1

k=√

2

2
𝛸∝,𝑛−1

1.64 2 𝑥 (9−1)
3.49

1

× (1 + ), n = 9, P = 0.90,∝= 0.10
9

1

No of Run
(Replication)
1 (1)
1 (2)
1 (3)
1 (4)
1 (5)
1 (6)
2 (1)
2 (2)
2 (3)
2 (4)
2 (5)
2 (6)
3 (1)
3 (2)
3 (3)
3 (4)
3 (5)
3 (6)

Xc (ppm)

Xf (ppm)

%R

80
80
80
80
80
80
100
100
100
100
100
100
120
120
120
120
120
120

89.9
88.8
87.2
88.4
86.4
88.1
109.1
109.2
108.0
108.2
108.0
109.0
132.1
131.6
129.6
128.4
129.6
133.0

112.4
111.0
109.0
110.5
108.0
110.1
109.1
109.2
108.0
108.2
108.0
109.0
110.1
109.7
108.0
107.0
108.0
110.8

*Unpublished data

× (1 + ) = 2.63
9

k can be obtained using the factors shown in Table XI for
TI of the URL of Appendix A Statistical Table [47],
whereas 𝑌̅ ± 𝑇𝐼 can be estimated using the Interactive
̅̅̅̅̅
Statistic Page link [48]. The calculations show that %𝑅
± PI/TI are included in the specification range (−2% to
1%).
Drug products. Table 7 shows the result of analytical
method validation of DP in three runs with different
concentration levels, and each run is carried out in six
replications. The acceptance criteria of 100 ppm were as
follows: accuracy: 85%–110%, bias: −15% to +10%,
RSD repeatability: 4% (Table 1).
̅̅̅̅̅ =109.2, SD= 1.40; RSD= 1.27, Recovery
Accuracy: %𝑅
curve = Xf = 2.6861 + 1.0646Xc: CIa = 2.6861 ± 4.0840,
CIb= 1.0646 ± 0.040306 (p = 0.05, not include 0); CIa =
2.6861 ± 7.7349, CIb = 1.0646 ± 0.7633 (p = 0.01, 0 is
included).
This evaluation shows that the recommendation of ICH
Q14 [29] regarding the acceptance criteria of slope (0.8–
1.25) should be further optimized (P = 0.05 or 0.01; see
2.1.).
Using ANOVA (Equations 7–9), 𝑆𝑟2 = 1.6277; 𝑆𝐵2 =
0.42048; 𝑆𝑅2 = 2.0481.
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Table 7. Drug Products*

0.42048

1.6277

Equation 10: CV mean =
+
= 0.140 + 0.09
3
3𝑥6
= 0.23
CIB = (109.2 − 100%) ± (1.74 × 1.40/√18) = 10.48 ± 0.57
= 9.91 to 11.05 % (α = 0.05)
CISD = 1.40√

18−1
8.67

= 2.75

𝑌̅ ± 𝑃𝐼 = 109.2 ± 1.74 × 1.40√1 +

1
18

= 109.2

± 2.50; 106.7% to 111.7%
𝑌̅ ± 𝑇𝐼 (𝑘 𝑥 𝑆𝐷)= 109.2 ± 2.19 × 1.40 = 109.2 ± 3.07:
106.1% to 112.3%
Evaluation of accuracy and precision using the
comparison method [7]. The result of the new and
validated procedures for homogenous test materials
(Section internal quality control) was analyzed using the
data presented in Table 8: 𝑛𝑁 = 𝑛𝑂 = 15 (power = 0.808);
α = 0.05
𝑑𝑓 =

0.214 0.159 2
+ 15 )
15
0.2142
0.1592
+
152 (15−1) 152(15−1)

(

= 27.4 = 27 (Equation 22)

0.214

𝐶𝐼𝜇𝐷 = 100.8 − 99.85 ± 1.703√

15

+

0.159
15

=

⌈−0.04; 0.50⌉ (Equation 22)
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Table 8. Results of Sample Analysis (n = 15)*

Procedure

̅ (%)
𝒀

New (N)
Validated (O)

𝑺𝑫𝟐

𝑌̅𝑁 = 100.08

𝑆𝐷𝑁2

= 0.214

𝑌̅𝑂 = 99.85

𝑆𝐷𝑂2

= 0.159

*Modified from Ref. [7]

CISD =

√0.214
√0.159

√

1
0.402

= 1.83 (Equation 23)

Non-homogenous test materials with 𝑛𝑁 = 𝑛𝑂 = 18
̅ = 0.39; 𝑆𝐷𝐷2 =0.350; α = 0.05; 𝑆𝐷𝑂2 =
(power = 0.803); 𝐷
0.16 were measured as follows (data from Ref. [7]):
0.350

𝐶𝐼𝐷̅ = 0.39 ± 1.74√

𝐶𝐼 𝑜𝑓 𝑆𝐷𝐷̅ = √

18

= ⌈0.15 𝑡𝑜 0.63⌉

(18−1).0.350
0.16 ×8.67

(Equation 25)

= 1.81 (Equation 26)

Conclusions and Recommendations
Conclusions and Recommendations: (1) The abovementioned examples show that evaluation using the
limits of accuracy and precision (Table 1) described by
current USP and FI cannot be used to draw valid
conclusions. Although 𝑅̅ and precision meet the
requirements, CIa and CIb could not meet the
requirements (5.1 and 5.2.2). The author recommends
revising the method of assessment in chapters <1225> of
the USP-NF [1] and <1381> of the FI VI [4], that is,
“Assessment of accuracy can be accomplished in a
variety of ways, including evaluating the recovery of the
analyte (percent recovery) across the range of the assay,
or evaluating the linearity of the relationship between
estimated and actual concentrations”. The term “or”
should be replaced with “and”. (2) As discussed in
section selection of SD and the methods of evaluations,
the application of a combined evaluation using Equation
14 is recommended in evaluating the accuracy and
precision of a proposed/new method. (3) The recovery
data must be reported as mean ± CI/PI/TI instead of mean
± SD/RSD (Sections combined evaluation of accuracy
and precision and selection of SD and the methods of
evaluations). (4) Further works are needed to determine
whether the comparison method using concordance
correlations can replace the methods proposed in the USP
chapter <1010> [7]. In evaluating the accuracy and
precision using the comparison method, a significance
test with a certain p-value should not be applied (Section
summary of the comparison method). (5) In obtaining
reliable data at a QC laboratory, the application of
internal quality control (Section internal quality control)
is strongly recommended. The internal quality control
must be included in the new edition of the Indonesian
Pharmacopeia.
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